Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.32 |
| ▸ | MTOR | P42345 | 2/20 | 0.32 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24782527 | 0.87 | — | — | |
| SCHEMBL3436929 | 0.79 | CHRM2 (0.48) | LTA4HGRIN1GRIN2ACHRM2CHRM3 | |
| SCHEMBL13460109 | 0.79 | GRIN1 (0.40) | LTA4HGRIN1GRIN2ACHRM2CHRM3 | |
| SCHEMBL25738952 | 0.79 | GRIN1 (0.40) | LTA4HGRIN1GRIN2ACHRM2CHRM3 | |
| SCHEMBL26456980 | 0.77 | GRIN1 (0.42) | LTA4HGRIN1GRIN2ACHRM2CHRM3 | |
| SCHEMBL15564387 | 0.75 | HTR2A (0.36) | LTA4HGRIN1GRIN2ACHRM2CHRM3 | |
| SCHEMBL19249615 | 0.75 | LTA4H (0.35) | LTA4HGRIN1GRIN2ACHRM2CHRM3 | |
| SCHEMBL16190002 | 0.74 | GRIN1 (0.42) | LTA4HGRIN1GRIN2ACHRM2CHRM3 | |
| SCHEMBL345569 | 0.73 | LTA4H (0.34) | LTA4HGRIN1GRIN2ACHRM2CHRM3 | |
| SCHEMBL25476574 | 0.73 | CHRM2 (0.41) | LTA4HGRIN1GRIN2ACHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024102952-A1 | SOS1 INHIBITORS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2024-05-16 | — | — | WO | disclosed |